Financial Lp Qvt Sells 876,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the completion of the transaction, the director now owns 22,179,358 shares in the company, valued at $262,160,011.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $11.48 on Friday. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.24. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. The company’s fifty day moving average is $11.50 and its two-hundred day moving average is $11.08. The firm has a market capitalization of $8.48 billion, a P/E ratio of 2.27 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The business had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. During the same period in the previous year, the firm earned ($0.38) EPS. The business’s revenue for the quarter was up 155.1% compared to the same quarter last year. Analysts forecast that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in shares of Roivant Sciences in the 2nd quarter worth about $34,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences in the 2nd quarter valued at about $36,000. Quarry LP acquired a new position in Roivant Sciences in the 2nd quarter valued at about $53,000. Acadian Asset Management LLC acquired a new position in Roivant Sciences in the 1st quarter valued at about $72,000. Finally, Fifth Third Wealth Advisors LLC acquired a new position in Roivant Sciences in the 2nd quarter valued at about $101,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ROIV shares. Bank of America lifted their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Piper Sandler lifted their price objective on shares of Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Thursday, September 19th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.39.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.